SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has raised concerns about future competition and weighed heavily on T-Mobile shares. Traders are split between viewing Starlink as a long-term threat and calling the selloff an overreaction, arguing that building a competitive network will take substantial time and infrastructure.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has intensified concerns about future competition, weighing on AT&T and other major wireless carriers. Traders are split between viewing the sharp selloff as an overreaction given the time and infrastructure needed to build a rival network and seeing a credible long-term threat; some are buying the dip for AT&Ts dividend.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

Exchange-delisting concerns are fueling bearish discussion, with traders debating the significance of Upbit and other platform changes; some holders argue the changes are limited or being mischaracterized. Bulls counter with JasmyChain activity and ecosystem partnerships as signs of development, while acknowledging that real adoption and token demand remain unproven.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention for Starknets privacy and Bitcoin DeFi push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are reacting to renewed price and volume momentum, while skeptics point to token unlocks and lingering supply pressure.

Chevron Corporation. The Group's principal activities are providing administrative, financial and management support for fully integrated petroleum, chemicals and coal mining operations. Exploration and production operations consist of exploring, developing and producing crude oil and natural gas and marketing natural gas. Refining, marketing and transportation operations relate to refining crude oil into finished petroleum products, marketing crude oil, natural gas and transporting crude oil, natural gas and petroleum products. Chemical operations include manufacture and marketing of commodity petrochemicals, plastics for industrial uses and fuel and lubricant oil additives. The Other operations consist of coal mining operations, power generation business, worldwide cash management and debt financing activities, corporate administrative functions, insurance operations, real estate activities and technology companies.

Chevron Corp.

Middle East conflict and Strait of Hormuz supply risks are driving discussion of higher, volatile oil prices and Chevrons sensitivity to crude; traders debate whether the oil rally will translate into further gains for CVX or whether easing tensions and pullbacks in crude will weigh on shares. Chevrons planned Venezuela expansion is also discussed as a longer-term growth opportunity, with execution and political risks noted.

Zoracles

A sharp, high-volume rebound after a prolonged slide has sparked momentum and short-squeeze speculation, though traders disagree over whether the move can hold or is another brief pump. Some are also debating whether Zoras expansion into Solana-based attention markets could benefit the token, but the messages do not establish a confirmed catalyst for the surge.

AGNC Investment Corp. engages in the operation of a real estate investment trust. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by the United States government-sponsored enterprise or by the United States government agency. It also invests in other types of mortgage and mortgage-related securities, such as credit risk transfer securities and non-Agency residential and commercial mortgage-backed securities, where repayment of principal and interest is not guaranteed by the United States government-sponsored enterprise or by the United States Government agency, and other assets related to the housing, mortgage, or real estate markets. The company was founded on January 7, 2008 and is headquartered in Bethesda, MD.

AGNC Investment Corp

Rising Treasury yields and mortgage-backed-securities repricing are weighing on AGNC, with traders pointing to falling book value and leverage as risks behind the sharp selloff. Some fear the monthly dividend could be cut, while others view the decline as an oversold buying opportunity and continue accumulating for the yield.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after a strong breakout to fresh highs, with traders pointing to momentum in software stocks and continued interest in AI-related observability. Bulls see the move continuing, while skeptics cite the stocks rich valuation and warn of a possible pullback.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax rallied alongside vaccine peers after reports of an NIH push to accelerate personalized cancer vaccines, with traders noting the move was largely sector-wide sympathy buying rather than a company-specific oncology announcement. The community also debated whether heavy short interest could amplify the move, while some pointed to Sanofis combination-vaccine trial as a separate potential catalyst.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

A joint extension in Aurinias patent litigation with generic-drug challengers has traders speculating that settlement discussions may be advancing, though the filing does not confirm a deal. The community is split between hopes that settlements could support a buyout and frustration that litigation delays and a lack of company news may keep the recent share-price bounce short-lived.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Equity

RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.


SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.


DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$16.64
Prev Close	$16.37
Open	$16.41
Dividend Yield	0.00%
50-Day Moving Average	$21.58
Beta	1.92
Avg. Volume	3.62M
PE Ratio	-4.99

52-Week High	$27.31
52-Week Low	$13.73
Market Capitalization	$3.06B
EPS (Annual)	-$3.47
Price to Book	3.93
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DYN Fundamentals